Item 8.01 Other Events

On May 26, 2020, Cumberland announced a new publication in Drugs - Real World Outcomes, detailing the positive clinical outcomes with Vibativ® in treating patients with bacteremia or endocarditis.

The Telavancin Observational Use Registry (TOUR™) was conducted to record population characteristics, prescription information, and real-world clinical outcomes of patients with Gram-positive infections treated with Vibativ. This publication assessed 151 patients in TOUR™ with endocarditis and/or bacteremia with a known or unknown primary source.

A copy of the press release is furnished as Exhibit 99.1 .

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses